NCT06566469View on ClinicalTrials.gov

Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium

PHASE4CompletedINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

May 1, 2025

Conditions
Older PatientsNasal AdministrationDexmedetomidineEsketamineGeneral AnesthesiaEmergence Delirium
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.

DRUG

Esketamine

Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.

DRUG

Normal saline

Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06566469 - Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium | Biotech Hunter | Biotech Hunter